A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases

A. M. Yeager, H. S. Singer, J. R. Buck, Reuben Matalon, S. Brennan, S. O. O'Toole, H. W. Moser

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

To determine whether allografts of normal amniotic epithelium might provide a nonimmunogenic cellular source of exogenous lysosomal enzymes, subcutaneous implants of amniotic epithelium were performed in six children with clinically advanced storage diseases. The clinical and the biochemical status of each patient was observed for several weeks after amniotic epithelial cell implantation (AECI). Serial studies of blood samples from each patient in the post-AECI period did not demonstrate any increase in levels of deficient lysosomal hydrolase. In two patients, quantitative urinary excretion of substrate was also studied and did not show consistent alterations after AECI. No patient had objective improvement in clinical or neurodevelopmental status following AECI. Two patients died with progressive disease at 2 1/2 and 3 1/2 mo after AECI; no residual amniotic epithelium was found at postmortem examination. Four patients are alive with progressive disease at 6-14 mo after AECI. We conclude that allografts of normal human amnion do not provide sufficient replacement hydrolases for clinical or biochemical improvement in lysosomal storage diseases.

Original languageEnglish (US)
Pages (from-to)347-355
Number of pages9
JournalAmerican Journal of Medical Genetics
Volume22
Issue number2
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Lysosomal Storage Diseases
Epithelial Cells
Epithelium
Hydrolases
Allografts
Therapeutics
Amnion
Autopsy
Enzymes

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. / Yeager, A. M.; Singer, H. S.; Buck, J. R.; Matalon, Reuben; Brennan, S.; O'Toole, S. O.; Moser, H. W.

In: American Journal of Medical Genetics, Vol. 22, No. 2, 1985, p. 347-355.

Research output: Contribution to journalArticle

Yeager, A. M. ; Singer, H. S. ; Buck, J. R. ; Matalon, Reuben ; Brennan, S. ; O'Toole, S. O. ; Moser, H. W. / A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. In: American Journal of Medical Genetics. 1985 ; Vol. 22, No. 2. pp. 347-355.
@article{ded493f387624399b4b23f2aa62bda15,
title = "A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases",
abstract = "To determine whether allografts of normal amniotic epithelium might provide a nonimmunogenic cellular source of exogenous lysosomal enzymes, subcutaneous implants of amniotic epithelium were performed in six children with clinically advanced storage diseases. The clinical and the biochemical status of each patient was observed for several weeks after amniotic epithelial cell implantation (AECI). Serial studies of blood samples from each patient in the post-AECI period did not demonstrate any increase in levels of deficient lysosomal hydrolase. In two patients, quantitative urinary excretion of substrate was also studied and did not show consistent alterations after AECI. No patient had objective improvement in clinical or neurodevelopmental status following AECI. Two patients died with progressive disease at 2 1/2 and 3 1/2 mo after AECI; no residual amniotic epithelium was found at postmortem examination. Four patients are alive with progressive disease at 6-14 mo after AECI. We conclude that allografts of normal human amnion do not provide sufficient replacement hydrolases for clinical or biochemical improvement in lysosomal storage diseases.",
author = "Yeager, {A. M.} and Singer, {H. S.} and Buck, {J. R.} and Reuben Matalon and S. Brennan and O'Toole, {S. O.} and Moser, {H. W.}",
year = "1985",
doi = "10.1002/ajmg.1320220219",
language = "English (US)",
volume = "22",
pages = "347--355",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases

AU - Yeager, A. M.

AU - Singer, H. S.

AU - Buck, J. R.

AU - Matalon, Reuben

AU - Brennan, S.

AU - O'Toole, S. O.

AU - Moser, H. W.

PY - 1985

Y1 - 1985

N2 - To determine whether allografts of normal amniotic epithelium might provide a nonimmunogenic cellular source of exogenous lysosomal enzymes, subcutaneous implants of amniotic epithelium were performed in six children with clinically advanced storage diseases. The clinical and the biochemical status of each patient was observed for several weeks after amniotic epithelial cell implantation (AECI). Serial studies of blood samples from each patient in the post-AECI period did not demonstrate any increase in levels of deficient lysosomal hydrolase. In two patients, quantitative urinary excretion of substrate was also studied and did not show consistent alterations after AECI. No patient had objective improvement in clinical or neurodevelopmental status following AECI. Two patients died with progressive disease at 2 1/2 and 3 1/2 mo after AECI; no residual amniotic epithelium was found at postmortem examination. Four patients are alive with progressive disease at 6-14 mo after AECI. We conclude that allografts of normal human amnion do not provide sufficient replacement hydrolases for clinical or biochemical improvement in lysosomal storage diseases.

AB - To determine whether allografts of normal amniotic epithelium might provide a nonimmunogenic cellular source of exogenous lysosomal enzymes, subcutaneous implants of amniotic epithelium were performed in six children with clinically advanced storage diseases. The clinical and the biochemical status of each patient was observed for several weeks after amniotic epithelial cell implantation (AECI). Serial studies of blood samples from each patient in the post-AECI period did not demonstrate any increase in levels of deficient lysosomal hydrolase. In two patients, quantitative urinary excretion of substrate was also studied and did not show consistent alterations after AECI. No patient had objective improvement in clinical or neurodevelopmental status following AECI. Two patients died with progressive disease at 2 1/2 and 3 1/2 mo after AECI; no residual amniotic epithelium was found at postmortem examination. Four patients are alive with progressive disease at 6-14 mo after AECI. We conclude that allografts of normal human amnion do not provide sufficient replacement hydrolases for clinical or biochemical improvement in lysosomal storage diseases.

UR - http://www.scopus.com/inward/record.url?scp=0022186458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022186458&partnerID=8YFLogxK

U2 - 10.1002/ajmg.1320220219

DO - 10.1002/ajmg.1320220219

M3 - Article

C2 - 3931477

AN - SCOPUS:0022186458

VL - 22

SP - 347

EP - 355

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 2

ER -